Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-CSF support with CHOP in elderly patients with aggressive non-Hodgkin lymphoma
ISRCTN26340837Phase 3Completed
- Sponsor
- HOVON
- Start
- Aug 1994
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of filgrastim, cyclophosphamide, doxorubicin, vincristine and prednisone in non-Hodgkin lymphoma (NHL) (2 arms), sponsored by HOVON. Primary endpoint: Complete remission rate. Started Aug 1994; status: completed.
02
Drugs
filgrastimcyclophosphamidedoxorubicinvincristineprednisone
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on ISRCTN26340837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN26340837.